NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
August 7, 2007 • Volume 4 / Number 23 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Common Cancers May Involve Fused Gene

Director's Update
Trial Breaks New Ground in Collaborative Research

Cancer Research Highlights
Treatment Regimen Effective for Metastatic Testicular Cancer

PET Can Predict Hodgkin Lymphoma Relapse

Inactivated Gene May Indicate Aggressive Lung Cancer

Guidelines Address Neurocognitive Problems in Childhood Cancer Survivors

FDA Update
ODAC Recommends Raloxifene Approval for Breast Cancer Prevention

Featured Clinical Trial
Adjuvant Treatment for Resected Lung Cancer

Notes
Ray Named Deputy Director for Management

Steeg Named a Deputy Editor of Clinical Cancer Research

All-Ireland NCI Cancer Consortium Web Site Wins Award

Funding Opportunities

NCI 70th Anniversary: If Memory Serves...

CCOP Profile
Columbia River Oncology Program

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Common Cancers May Involve Fused Genes

New research suggests that gene fusion - the coming together of DNA from different parts of the genome - may be an important event in the development of common cancers.

Fused genes and the chromosomal rearrangements that cause them are a hallmark of leukemia, lymphomas, and other blood cancers, but they were not identified in a solid tumor until 2005. In a landmark study, Dr. Arul Chinnaiyan of the University of Michigan Medical School and his colleagues reported that 70 percent of prostate cancers may harbor fused genes.  Read more  



Director's Update

Trial Breaks New Ground in Collaborative Research

Last month a teenage girl from Indiana became the first patient enrolled in an important early-phase NCI clinical trial at the NIH Clinical Center. Diagnosed with an aggressive form of a rare cancer, hereditary medullary thyroid carcinoma (MTC), this young woman will help determine whether the investigational agent vandetanib may be the first effective nonsurgical treatment in young patients with this cancer.

The trial is significant for another reason. It's the first being conducted at the NIH Clinical Center under the joint leadership of an NIH intramural clinical investigator and an extramural scientist. Dr. Frank Balis, from the Pediatric Oncology Branch in NCI's Center for Cancer Research (CCR), is the principal investigator (PI), while Dr. Samuel Wells, from Washington University in St. Louis and one of the world's foremost MTC experts, is the adjunct PI.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov